Breaking News

Duke to Expedite Study of COVID-19 Prevention in Healthcare Workers

The Patient-Centered Outcomes Research Institute has funded up to $50 million to evaluate hydroxychloroquine as a preventive drug for the novel coronavirus

By: Contract Pharma

Contract Pharma Staff

A new rapid-response study designed and led by the Duke Clinical Research Institute (DCRI) seeks to engage healthcare workers across the nation to understand the impact of COVID-19 on their health and to evaluate whether hydroxychloroquine can prevent COVID-19 infections in healthcare workers at high risk of contracting this novel coronavirus.   The launch of the Healthcare Worker Exposure Response and Outcomes (HERO) research program was unveiled by the Patient-Centered Outcomes Research Instit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters